Print page |
E-mail page
| 
Download PDF
|
Add to briefcase
« Previous Release | Next Release »
Charlottesville, Virginia. July 5, 2005 -- Adenosine Therapeutics, LLC, a leading adenosine drug discovery and development company, announced today it has been awarded a Fast Track Phase I/II Small Business Innovation Research (SBIR) grant from the Department of Health and Human Services at the National Institute of Health. The grant will fund the clinical development of the Company’s lead compound, ATL-146e, to prevent reperfusion injury. The amount of the award is approximately $2.0 million, and will be used to support the completion of Phase I and Phase II clinical trials to develop a drug to prevent cardiac reperfusion injury.
“The primary goal of
this project is to expedite clinical testing to evaluate the effectiveness
of ATL-146e in protecting the heart against additional damage associated
with the reopening of a blocked vessel. This may occur in patients who
suffer an acute myocardial infarction (heart attack),” said Dr.
Shannon Williams, VP Regulatory and Clinical Development and Principal
Investigator for the grant.
AMI is the leading single cause of death in the US, resulting in 500,000
– 700,000 mortalities annually.
About Adenosine
Therapeutics
Adenosine Therapeutics focuses on the discovery and development of novel
pharmaceutical products that target adenosine receptor subtypes. Candidates
for drug development are identified and screened using the company’s
state-of-the-art adenosine receptor screening platform technology. The
company was founded with the goal of taking new adenosine-receptor selective
drugs into clinical trials for a broad range of potential indications.
These drug indications include inflammatory indications, sepsis, heart
attack, ischemia-reperfusion injury, vascular injury, spinal cord injury,
COPD, asthma, diabetes, inflammatory bowel disease, retinopathy, epilepsy,
Parkinson’s disease, and site-specific angiogenesis. The company’s
most advanced drug development program is in Phase II clinical development.
For more information on Adenosine Therapeutics, visit our web site at
www.adenrx.com.